FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer

Copenhagen, Denmark, 24 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received approvals to initiate the phase II trial in lung cancer. The trial is expected to enrol first patient in Q2.

The release as fetched from its publisher. fluoguide.com ↗